Summary of Conference Call Industry Overview - The conference call focused on the aesthetic medicine industry, particularly in the context of recent changes and developments in the market, including new product launches and regulatory challenges [1][2]. Key Points and Arguments - **Market Recovery Post-Spring Festival**: The industry experienced a slow recovery after the Spring Festival, with only about 20 operational days in February, leading to a performance completion rate of approximately 94.3% for that month [2][4]. - **Customer Segmentation**: In the first two months, the customer base consisted of 58% returning customers and 42% new customers. The average transaction value for new customers was approximately 3,632, while for returning customers, it was 7,113 [2][9]. - **Department Performance**: The dermatology department led the market with a 36.2% share, followed closely by minimally invasive procedures at 35.1%, and plastic surgery at 28.5% [3]. - **Year-on-Year Growth**: The company reported a year-on-year growth of 7.9% for the first two months, with January achieving a completion rate of 108% of its targets, while February fell short [3][4]. - **Sales Targets**: The company aims to meet its quarterly earnings targets, with a remaining gap of 2.67 billion to achieve the goal for March [4][5]. - **Competitive Landscape**: The company noted that its competitors also showed reasonable growth rates, with Huakou at 7.5%, Meilai at 9.1%, and other players like Lianhe Ligao and Langsi around 6.1% to 7% [5]. Product Launch and Market Response - **New Product Launch**: The company launched a new product, which faced initial challenges due to negative media coverage and customer refunds, impacting sales expectations [10][11]. - **Customer Feedback**: Despite the challenges, the company has seen a steady interest in the new product, with over 2,100 customers registered for the treatment within a short period [17]. - **Sales Performance of Key Products**: Key products like Aisufei and Weimei showed growth, with Aisufei's sales increasing by 14% year-on-year [18][19]. Regulatory Environment - **Impact of Regulations**: The company expressed concerns about the regulatory environment, noting that strict regulations could hinder market acceptance and growth, particularly for new products [12][14]. - **Market Perception**: There is a perception issue in the market due to negative reports about the industry, which could affect customer trust and product acceptance [12][13]. Additional Insights - **Online Sales Growth**: The proportion of online customers increased from 58% to 68% year-on-year, indicating a shift towards digital engagement strategies [9]. - **Promotional Activities**: The company plans to leverage traditional promotional periods in March to boost sales, expecting a significant increase in new customer acquisition [6][7]. Conclusion - The aesthetic medicine industry is navigating a complex landscape with both opportunities and challenges. The company remains optimistic about meeting its targets while adapting to market dynamics and regulatory pressures [21].